Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.
C RyanA MenterL GuentherAndrew BlauveltRobert BissonnetteK MeeuwisJ SullivanJ C CatherG YosipovitchA B GottliebJ F MerolaK Callis DuffinS FretzinO O OsuntokunR BurgeA N NaegeliF E YangC-Y LinK ToddA Potts Bleakmannull nullPublished in: The British journal of dermatology (2018)
Ixekizumab was superior to placebo for the treatment of moderate-to-severe GenPs with BSA ≥ 1%. The safety profile of ixekizumab was consistent with previous studies in moderate-to-severe plaque psoriasis.